8-K: VBI Vaccines Granted Second Extension to Regain Nasdaq Compliance

VBI Vaccines has received a second 180-day extension from Nasdaq to meet the minimum bid price requirement for continued listing.

Summary

• VBI Vaccines initially received a notice from Nasdaq on November 1, 2023, for not meeting the minimum bid price of $1.00 per share.
• The company was given a 180-day compliance period, which was set to end on April 29, 2024.
• On April 30, 2024, Nasdaq granted VBI Vaccines an additional 180-day extension, until October 28, 2024, to regain compliance.
• This extension was granted because VBI Vaccines met all other listing requirements except for the minimum bid price.
• VBI Vaccines has indicated its intention to cure the deficiency, potentially through a reverse stock split.
• If the company fails to meet the minimum bid price by October 28, 2024, it could face delisting from the Nasdaq Capital Market.
• VBI Vaccines has the option to appeal any delisting decision to a Nasdaq Hearings Panel.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the continued non-compliance with Nasdaq listing rules and the risk of delisting. The need for a potential reverse stock split also adds to the negative outlook.

Positives

• Nasdaq has granted VBI Vaccines a second extension, providing more time to regain compliance.
• The company has met all other listing requirements except for the minimum bid price.
• VBI Vaccines has indicated its intention to cure the deficiency, showing a proactive approach.

Negatives

• VBI Vaccines is still not in compliance with the Nasdaq minimum bid price requirement.
• There is a risk of delisting if the company fails to meet the requirement by October 28, 2024.
• The company may need to implement a reverse stock split to regain compliance, which could negatively impact shareholders.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market if it does not meet the minimum bid price requirement by October 28, 2024.
• There is no guarantee that the company will be able to regain compliance, even with the extension.
• A reverse stock split, if implemented, could negatively impact the share price and shareholder value.

Future Outlook

The company intends to cure the deficiency, potentially through a reverse stock split, but there is no assurance that it will be able to regain compliance and maintain its listing on the Nasdaq Capital Market.

Management Comments

• The company has indicated its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

Industry Context

This announcement is specific to VBI Vaccines' compliance with Nasdaq listing rules and does not directly reflect broader industry trends. However, it highlights the challenges that some smaller biotech companies face in maintaining their stock price and meeting exchange requirements.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining their share price above the minimum bid price required by exchanges like Nasdaq.
• Reverse stock splits are a common strategy used by companies to regain compliance, but they can be viewed negatively by investors.
• Other companies in the biotech sector have faced similar delisting risks and have had to implement similar strategies to maintain their listing.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may be concerned about the company's future and job security.
• The company's reputation and ability to raise capital may be negatively impacted.

Next Steps

• VBI Vaccines needs to regain compliance with the minimum bid price requirement by October 28, 2024.
• The company may implement a reverse stock split to increase its share price.
• The company may appeal any delisting determination to a Nasdaq Hearings Panel if necessary.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, delisting, reverse stock split, VBI Vaccines, listing rules